Novel Compound for Neural Damage Treatment - Etnova Therapeutics, EP4166544A1
Summary
Etnova Therapeutics Corp. and Kyungpook National University Industry-Academic Cooperation Foundation filed European patent application EP4166544A1 for a novel compound and pharmaceutical composition for treating or preventing neural damage, neural disease, or developmental disorder by promoting neural cell proliferation, differentiation, and/or regeneration. The EPO published the application on April 15, 2026 (Kind A1, with search report). Five inventors are named: CHANG Sha Joung, KIM Yeoun Hee, LEE Jung Jin, CHOI Ga Ram, and CHANG Yong Min. The application covers IPC classes C07D 257/02, A61K 31/395, A61P 25/00, and A61P 25/28, designating 25 European states.
About this source
GovPing monitors EPO Patent Bulletin - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 24 changes logged to date.
What changed
The EPO published patent application EP4166544A1 for a novel heterocyclic compound (C07D 257/02) and associated pharmaceutical composition (A61K 31/395) intended for neurological therapeutic use. The application specifically covers methods of treating or preventing neural damage, neural diseases, and developmental disorders through promoting proliferation, differentiation, and/or regeneration of neural cells (A61P 25/00, A61P 25/28).
Pharmaceutical and biotechnology companies engaged in neural regeneration research or developing competing neurological therapies should monitor the prosecution of this application, particularly in the designated contracting states. The patent, once granted, may create freedom-to-operate considerations for parties working in overlapping therapeutic areas.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME FOR TREATING OR PREVENTING NEURAL DAMAGE, NEURAL DISEASE, OR DEVELOPMENTAL DISORDER THROUGH PROMOTING PROLIFERATION, DIFFERENTIATION, AND/OR REGENERATION OF NEURAL CELLS
Publication EP4166544A1 Kind: A1 Apr 15, 2026
Applicants
Etnova Therapeutics Corp., Kyungpook National University Industry-Academic
Cooperation Foundation
Inventors
CHANG, Sha Joung, KIM, Yeoun Hee, LEE, Jung Jin, CHOI, Ga Ram, CHANG, Yong Min
IPC Classifications
C07D 257/02 20060101AFI20240426BHEP A61K 31/395 20060101ALI20240426BHEP A61P 25/00 20060101ALI20240426BHEP A61P 25/28 20060101ALI20240426BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.